What West Pharmaceutical Services's Quarter ended Sep 30, 2026 10-Q says: 4 signals
West Pharmaceutical Services filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses cybersecurity incident, divestiture and margin pressure.
Public (WST)Plastics Manufacturing10,000+ employeeswestpharma.comLinkedIn
Get West Pharmaceutical Services' live signals in Claude or ChatGPT, or by API
What changed at West Pharmaceutical Services this week? Use Autobound signals for westpharma.com.- Filed
- Oct 29, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 23
Source: Autobound Signal API · 51 signals tracked for West Pharmaceutical Services · updated
10-Q · latest 10
What West Pharmaceutical Services's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 4 signals
West Pharmaceutical sold SmartDose 3.5mL delivery system and facilities to AbbVie on July 1, 2026
The company completed the sale of its SmartDose 3.5mL On-Body Delivery System assets and associated facilities to AbbVie on July 1, 2026, recording a pre-tax net gain of $55.7 million.
$55.7M
net gain on the sale of SmartDose 3.5mL On-Body Delivery System assets
May 2026 Material Cyberattack Encrypted Systems, Exfiltrated Data, and Incurred SG&A Expenses
In May 2026, West Pharmaceutical Services experienced a cybersecurity incident involving data exfiltration, system encryption, and global operational disruption, incurring $9.2 million in SG&A expenses during the first nine months of 2026.
encryption
The company recorded pre-tax charges of $6.3 million for the quarter and $9.3 million year-to-date related to severance, accelerated depreciation, and legal structure optimization.
$6.3M
pre-tax restructuring charges for the three months ended September 30, 2026
West Vantage gross profit margin declines 2.8 percentage points to 16.5%
West Vantage gross profit dropped 20.8% to $24.0 million with gross margin falling by 2.8 percentage points due to product mix, plant inflationary pressures, and ramp-up costs.
16.5%
West Vantage gross profit margin for the three months ended September 30, 2026
- SEC EDGAR
10-Q
Filed · 9 signals
A recent cyberattack resulted in encrypted systems and stolen data, forcing a temporary global shutdown of operations.
artificial intelligence
New executive Michel Lagarde's employment agreement dated May 31, 2026, signals CEO change.
The company filed an executive employment agreement for Michel Lagarde, indicating a change in top leadership.
Facing securities class action lawsuit alleging violations of the Securities Exchange Act.
The company and certain officers are defendants in a class action lawsuit over public statements and stock transactions, creating significant legal risk and likely increasing spend on legal services and e-discovery tools.
CHRO Annette Favorite adopted a Rule 10b5-1 trading plan, signaling potential departure.
CHRO Annette Favorite established a plan on June 2, 2026, to sell up to 15,659 shares starting in September 2026.
Anticipates significant and increasing costs to mitigate data security risks after major incident.
Following a material cyberattack, the company explicitly states that costs to enhance systems and prevent future attacks will be significant and are likely to increase.
Identifies dependency on single-source Japanese partner Daikyo for critical materials.
The company explicitly states its dependence on its Japanese partner and affiliate, Daikyo, as a single-source supplier for critical products.
Daikyo
Earlier 10-Q filings
- 10-QFiled · 10 signalsSEC EDGAR
Showing 10 of 23 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
West Pharmaceutical Services earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Raised full-year revenue and earnings guidance on strong performance.The company increased its FY25 revenue forecast to $3.06-$3.07 billion and adjusted EPS to $7.06-$7.11, indicating strong business momentum and financial health. This suggests available budget and confidence in future growth. | |
| Annex 1 upgrade initiative accelerating, now expected to drive 200bps of growth.The company is seeing stronger-than-expected demand for upgrades related to new EU regulations (Annex 1), with 375 projects ongoing. This initiative is a key growth driver, creating opportunities for vendors who can support quality and compliance upgrades. | |
| Launching new drug handling business, expecting $20M revenue in 2026.The company is commercializing a new drug handling business in its Dublin facility, with production ramping in early 2026. This expansion into a new service line creates opportunities for vendors supporting new product introductions and manufacturing processes. | |
| Actively hiring and training to expand manufacturing capacity in Germany.The company is investing in its workforce to resolve production constraints at a key HVP manufacturing site. This indicates budget for talent acquisition, training, and operational support to fuel growth. | |
| Capital expenditures decreasing to $275M after a period of elevated spending.While CapEx is down 23% year-to-date compared to last year, the company is still on track to spend a substantial $275 million in 2025. This normalization frees up cash flow but still represents significant investment in facilities and equipment. | |
| New CFO is establishing a new capital allocation policy.The new CFO is actively reviewing and defining a new capital allocation policy to better deploy the company's strong cash flow. This strategic shift could influence future M&A, buybacks, and major internal investment decisions, creating openings for financial and strategic advisory services. |
Signal API · MCP
Track West Pharmaceutical Services with the Signal API
One POST /v1/companies/enrich call with westpharma.com returns West Pharmaceutical Services 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"westpharma.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
Related companies
Questions about West Pharmaceutical Services 10-Q
When did West Pharmaceutical Services file its latest 10-Q?
What did West Pharmaceutical Services disclose in its latest 10-Q?
What did West Pharmaceutical Services say on its recent earnings calls?
Where can I read West Pharmaceutical Services's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .